Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2020 | 2 |
2021 | 2 |
2023 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
melanie co
(499 results)?
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15.
Clin Cancer Res. 2021.
PMID: 34526366
Free PMC article.
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H, Novotny W, Co M, Romano A, Holmgren E, Huang J, Gouill SL.
Dreyling M, et al. Among authors: co m.
Future Oncol. 2021 Jan;17(3):255-262. doi: 10.2217/fon-2020-0794. Epub 2020 Sep 28.
Future Oncol. 2021.
PMID: 32985902
Clinical Trial.
Item in Clipboard
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J.
Opat S, et al. Among authors: co m.
Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668.
Blood Adv. 2023.
PMID: 37682792
Free PMC article.
Clinical Trial.
Item in Clipboard
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
Tatarczuch M, Waltham M, Shortt J, Polekhina G, Hawkes EA, Ho SJ, Trotman J, Brasacchio D, Co M, Li J, Ramakrishnan V, Dunne K, Opat SS, Gregory GP.
Tatarczuch M, et al. Among authors: co m.
Blood Adv. 2023 Jul 25;7(14):3531-3539. doi: 10.1182/bloodadvances.2022009412.
Blood Adv. 2023.
PMID: 36947202
Free PMC article.
Item in Clipboard
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, Beaupre DM, Neuenburg JK, Palomba ML.
Fowler NH, et al. Among authors: co m.
Br J Haematol. 2020 May;189(4):650-660. doi: 10.1111/bjh.16424. Epub 2020 Mar 16.
Br J Haematol. 2020.
PMID: 32180219
Free PMC article.
Item in Clipboard
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, Elion R, Blick G, Khatri A, Hu YB, Gibbons K, Fredrick L, Co M, D'Amico R, Da Silva-Tillmann B, Trinh R, Sulkowski MS.
Eron JJ, et al. Among authors: co m.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19500. doi: 10.7448/IAS.17.4.19500. eCollection 2014.
J Int AIDS Soc. 2014.
PMID: 25394009
Free PMC article.
Item in Clipboard
Cite
Cite